GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rang in aandelen
#3633
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aandeelprijs
$27.54
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$4.67B
Verandering (1 dag)
-2.73%
Verandering (1 jaar)
-11.86%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categorie
Healthcare
EPS voor GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
EPS per June 2026 TTM: $0.70
Volgens de laatste financiële rapporten en de aandelenkoers van GlaxoSmithKline Pharmaceuticals Limited is de huidige EPS van het bedrijf (TTM) $0.70. Eind 2024 had het bedrijf een EPS van $0.42, een daling ten opzichte van de EPS van 2023 die $0.44 bedroeg.
EPS-geschiedenis van GlaxoSmithKline Pharmaceuticals Limited van 2004 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.70 | 8.72% |
| 2025 | $0.64 | 53.29% |
| 2024 | $0.42 | -4.31% |
| 2023 | $0.44 | 55.78% |
| 2022 | $0.28 | 20.93% |
| 2021 | $0.23 | 217.40% |
| 2020 | $0.07 | -80.72% |
| 2019 | $0.38 | 19.09% |
| 2018 | $0.32 | 3.69% |
| 2017 | $0.31 | -8.50% |
| 2016 | $0.34 | -7.07% |
| 2015 | $0.36 | -0.91% |
| 2013 | $0.36 | -39.74% |
| 2012 | $0.60 | 26.71% |
| 2011 | $0.48 | -35.63% |
| 2010 | $0.74 | 14.81% |
| 2009 | $0.64 | -10.33% |
| 2008 | $0.72 | -12.43% |
| 2007 | $0.82 | 11.92% |
| 2006 | $0.73 | 11.91% |
| 2005 | $0.66 | 47.32% |
| 2004 | $0.45 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $29.89 | 4,195.77% |
US
|
|
| $6.60 | 848.55% |
US
|
|
| $3.55 | 410.20% |
US
|
|
| $1.26 | 81.09% |
US
|
|
| $20.39 | 2,830.30% |
CH
|
